175 related articles for article (PubMed ID: 9593726)
1. Alternative intracellular routing of ErbB receptors may determine signaling potency.
Waterman H; Sabanai I; Geiger B; Yarden Y
J Biol Chem; 1998 May; 273(22):13819-27. PubMed ID: 9593726
[TBL] [Abstract][Full Text] [Related]
2. Bivalence of EGF-like ligands drives the ErbB signaling network.
Tzahar E; Pinkas-Kramarski R; Moyer JD; Klapper LN; Alroy I; Levkowitz G; Shelly M; Henis S; Eisenstein M; Ratzkin BJ; Sela M; Andrews GC; Yarden Y
EMBO J; 1997 Aug; 16(16):4938-50. PubMed ID: 9305636
[TBL] [Abstract][Full Text] [Related]
3. Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers.
Lenferink AE; Pinkas-Kramarski R; van de Poll ML; van Vugt MJ; Klapper LN; Tzahar E; Waterman H; Sela M; van Zoelen EJ; Yarden Y
EMBO J; 1998 Jun; 17(12):3385-97. PubMed ID: 9628875
[TBL] [Abstract][Full Text] [Related]
4. The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing.
Waterman H; Alroy I; Strano S; Seger R; Yarden Y
EMBO J; 1999 Jun; 18(12):3348-58. PubMed ID: 10369675
[TBL] [Abstract][Full Text] [Related]
5. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.
Karunagaran D; Tzahar E; Beerli RR; Chen X; Graus-Porta D; Ratzkin BJ; Seger R; Hynes NE; Yarden Y
EMBO J; 1996 Jan; 15(2):254-64. PubMed ID: 8617201
[TBL] [Abstract][Full Text] [Related]
6. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired.
Baulida J; Kraus MH; Alimandi M; Di Fiore PP; Carpenter G
J Biol Chem; 1996 Mar; 271(9):5251-7. PubMed ID: 8617810
[TBL] [Abstract][Full Text] [Related]
7. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.
Graus-Porta D; Beerli RR; Daly JM; Hynes NE
EMBO J; 1997 Apr; 16(7):1647-55. PubMed ID: 9130710
[TBL] [Abstract][Full Text] [Related]
8. An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4.
Chen X; Levkowitz G; Tzahar E; Karunagaran D; Lavi S; Ben-Baruch N; Leitner O; Ratzkin BJ; Bacus SS; Yarden Y
J Biol Chem; 1996 Mar; 271(13):7620-9. PubMed ID: 8631797
[TBL] [Abstract][Full Text] [Related]
9. ErbB kinases and NDF signaling in human prostate cancer cells.
Grasso AW; Wen D; Miller CM; Rhim JS; Pretlow TG; Kung HJ
Oncogene; 1997 Nov; 15(22):2705-16. PubMed ID: 9400997
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers.
Stortelers C; van De Poll ML; Lenferink AE; Gadellaa MM; van Zoelen C; van Zoelen EJ
Biochemistry; 2002 Apr; 41(13):4292-301. PubMed ID: 11914075
[TBL] [Abstract][Full Text] [Related]
11. Ligands for ErbB-family receptors encoded by a neuregulin-like gene.
Chang H; Riese DJ; Gilbert W; Stern DF; McMahan UJ
Nature; 1997 May; 387(6632):509-12. PubMed ID: 9168114
[TBL] [Abstract][Full Text] [Related]
12. Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kinases.
Karunagaran D; Tzahar E; Liu N; Wen D; Yarden Y
J Biol Chem; 1995 Apr; 270(17):9982-90. PubMed ID: 7730382
[TBL] [Abstract][Full Text] [Related]
13. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms.
Tzahar E; Levkowitz G; Karunagaran D; Yi L; Peles E; Lavi S; Chang D; Liu N; Yayon A; Wen D
J Biol Chem; 1994 Oct; 269(40):25226-33. PubMed ID: 7929212
[TBL] [Abstract][Full Text] [Related]
14. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.
Pinkas-Kramarski R; Soussan L; Waterman H; Levkowitz G; Alroy I; Klapper L; Lavi S; Seger R; Ratzkin BJ; Sela M; Yarden Y
EMBO J; 1996 May; 15(10):2452-67. PubMed ID: 8665853
[TBL] [Abstract][Full Text] [Related]
15. Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity.
Kochupurakkal BS; Harari D; Di-Segni A; Maik-Rachline G; Lyass L; Gur G; Kerber G; Citri A; Lavi S; Eilam R; Chalifa-Caspi V; Eshhar Z; Pikarsky E; Pinkas-Kramarski R; Bacus SS; Yarden Y
J Biol Chem; 2005 Mar; 280(9):8503-12. PubMed ID: 15611079
[TBL] [Abstract][Full Text] [Related]
16. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor.
Tzahar E; Waterman H; Chen X; Levkowitz G; Karunagaran D; Lavi S; Ratzkin BJ; Yarden Y
Mol Cell Biol; 1996 Oct; 16(10):5276-87. PubMed ID: 8816440
[TBL] [Abstract][Full Text] [Related]
17. Growth factor-independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor-alpha.
Ethier SP; Langton BC; Dilts CA
Mol Carcinog; 1996 Feb; 15(2):134-43. PubMed ID: 8599580
[TBL] [Abstract][Full Text] [Related]
18. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors.
Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M
Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890
[TBL] [Abstract][Full Text] [Related]
19. ErbB signaling regulates lineage determination of developing pancreatic islet cells in embryonic organ culture.
Huotari MA; Miettinen PJ; Palgi J; Koivisto T; Ustinov J; Harari D; Yarden Y; Otonkoski T
Endocrinology; 2002 Nov; 143(11):4437-46. PubMed ID: 12399441
[TBL] [Abstract][Full Text] [Related]
20. Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells.
Ram TG; Kokeny KE; Dilts CA; Ethier SP
J Cell Physiol; 1995 Jun; 163(3):589-96. PubMed ID: 7775601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
